Recomendaciones sobre el tratamiento de la candidiasis invasiva y otras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011

Aguado, José María; Ruiz‐Camps, Isabel; Muñóz, Patricia; Mensa, José; Almirante, Benito; Vázquez, Lourdes; Rovira, Montserrat; Martín-Dávila, Pilar; Moreno, Asunción; Álvarez-Lerma, Francisco; León, Cristóbal; Madero, Luís; Ruiz–Contreras, Jesús; Fortün, Jesús; Cuenca‐Estrella, Manuel

doi:10.1016/j.eimc.2011.01.008

Cited by 64 publications

(13 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No se observó candidiasis en los pacientes con diabetes mellitus tipo 2 que participaron en el estudio; sin embargo, nuestro criterio no se asemeja al de otros autores (19,21) . En dichos estudios proponen que el uso de prótesis dental es el factor causante de la candidiasis.…”

Section: Discussionunclassified

Manifestaciones orales en pacientes con diabetes mellitus tipo 2 atendidos en el Hospital Alberto Sabogal

Linares-Vega¹,

Zavaleta-Solorzano²,

Siapo-García³

et al. 2017

Kiru

View full text Add to dashboard Cite

Determinar las manifestaciones orales más frecuentes de la diabetes mellitus tipo 2 durante el año 2016 en el Hospital Alberto Sabogal. Materiales y Métodos: Estudio descriptivo, transversal. Se evaluó a 47 pacientes con un rango de edades de < 40 años, 40-65 años y >= 65 años y en cuanto a razón femenina/masculino fue de 1/1, con diabetes mellitus tipo 2 del Hospital Sabogal, octubre de 2016. Los datos se recolectaron con una ficha que incluía variables sociodemográficas de los pacientes y evaluación de la cavidad oral. El análisis estadístico fue de distribución de frecuencias y de asociación de variables con chi 2. Resultados: El grupo etario más frecuente fue el de mayores de 65 años (48,94%). La hipertensión arterial fue la comorbilidad más frecuente (57,45%) y la retinopatía como complicación crónica (42,55%). El 63,83% usaba insulina. La manifestación oral más frecuente fue edentulismo parcial (85,11%), seguido de caries (82,98%), gingivitis (78,72%), periodontitis (57,45%), halitosis (48,94%), lengua saburral (40,53%), lengua fisurada (31,91%), xerostomía (21,28%), alteraciones del gusto (21.28%), aftas (14,89%) , herpes (6.38%), liquen plano (6,38%) y abscesos (2,13%). Ningún paciente tuvo candidiasis oral. Se obtuvo una relación significativa entre el edentulismo y el uso de insulina como tratamiento para la diabetes mellitus con un chi 2 = 4,42 y p = 0,03567. Conclusiones: La manifestación oral más frecuente fue el edentulismo parcial. Se obtuvo una relación entre el edentulismo y el uso de insulina.

show abstract

Section: Discussionunclassified

Manifestaciones orales en pacientes con diabetes mellitus tipo 2 atendidos en el Hospital Alberto Sabogal

Linares-Vega¹,

Zavaleta-Solorzano²,

Siapo-García³

et al. 2017

Kiru

View full text Add to dashboard Cite

show abstract

“…Para la profilaxis selectiva en estos pacientes de riesgo se ha utilizado y recomendado en las guías americanas sobre todo fluconazol y anfotericinas lipídicas (suponen un elevado riesgo de nefrotoxicidad para el paciente trasplantado), que en caso del pulmón pueden administrarse nebulizadas 71 . Recientemente se han realizado o se están llevando a cabo en el seno de GESITRA estudios que demuestran la eficacia de la profilaxis con candinas (caspofungina, anidulafungina y micafungina) durante la hospitalización, motivo por el que las recomendaciones españolas las han incorporado [72][73][74] .…”

Section: Medidas Preventivasunclassified

Infección nosocomial en el paciente receptor de un trasplante de órgano sólido o de precursores hematopoyéticos

Camacho

Ruiz‐Camps

2014

Enfermedades Infecciosas y Microbiología Clínica

View full text Add to dashboard Cite

Bacterial infections are the most common infections in solid organ transplant recipients. These infections occur mainly in the first month after transplantation and are hospital-acquired. Nosocomial infections cause significant morbidity and are the most common cause of mortality in this early period of transplantation. These infections are caused by multi-drug resistant (MDR) microorganisms, mainly Gram-negative enterobacteria, non-fermentative Gram-negative bacilli, enterococci, and staphylococci. The patients at risk of developing nosocomial bacterial infections are those previously colonized with MDR bacteria while on the transplant waiting list. Intravascular catheters, the urinary tract, the lungs, and surgical wounds are the most frequent sources of infection. Preventive measures are the same as those applied in non-immunocompromised, hospitalized patients except in patients at high risk for developing fungal infection. These patients need antifungal therapy during their hospitalization, and for preventing some bacterial infections in the early transplant period, patients need vaccinations on the waiting list according to the current recommendations. Although morbidity and mortality related to infectious diseases have decreased during the last few years in haematopoietic stem cell transplant recipients, they are still one of the most important complications in this population. Furthermore, as occurs in the general population, the incidence of nosocomial infections has increased during the different phases of transplantation. It is difficult to establish general preventive measures in these patients, as there are many risk factors conditioning these infections. Firstly, they undergo multiple antibiotic treatments and interventions; secondly, there is a wide variability in the degree of neutropenia and immunosuppression among patients, and finally they combine hospital and home stay during the transplant process. However, some simple measures could be implemented to improve the current situation.

show abstract

“…Patients with increased risk for candidemia and/or invasive candidiasis (IC) are: the patients admitted to the intensive care unit (ICU), neutropenic patients with cancer, patients undergoing surgical procedures, premature infants and other immunosuppressed patients. 1 , 2 In Spain, C. albicans is the most common species, followed by C. parapsilosis and C. tropicalis . 1 , 3 The incidence of candidemia in Spain is estimated at 4.3 episodes per 100,000 inhabitants, 1 , 3 with 33%–55% of episodes occurring in the ICU.…”

Section: Introductionmentioning

confidence: 99%

“… 1 , 2 In Spain, C. albicans is the most common species, followed by C. parapsilosis and C. tropicalis . 1 , 3 The incidence of candidemia in Spain is estimated at 4.3 episodes per 100,000 inhabitants, 1 , 3 with 33%–55% of episodes occurring in the ICU. 1 , 4 This proportion may have declined in recent years.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients

Grau¹,

Pozo²,

Romá³

et al. 2015

CEOR

View full text Add to dashboard Cite

ObjectiveTo estimate the cost-effectiveness of three echinocandins (anidulafungin, caspofungin, and micafungin) and generic fluconazole in the treatment of nonneutropenic adult patients with candidemia and/or invasive candidiasis in intensive care units in Spain.Materials and methodsA decision-tree model was applied. The success and safety (hepatic and renal adverse effects) of first-line treatments were obtained from meta-analyses and systematic reviews of clinical trials. In the case of failure, a second-line treatment (liposomal amphotericin B after the echinocandins, or one of the echinocandins after fluconazole) was administered. The duration of the treatments (14 days total) was established by a panel of clinical experts using the Delphi method and according to Infectious Diseases Society of America guidelines. The cost of the medications and renal toxicity were considered. Deterministic and probabilistic sensitivity analysis using Monte Carlo simulations were carried out.ResultsThe total cost of the treatment of candidemia and/or invasive candidiasis with anidulafungin, caspofungin, micafungin, and fluconazole was €5,483, €5,968, €6,231, and €2,088, respectively. Anidulafungin was the dominant treatment (more effective, less expensive) compared to micafungin and caspofungin. The cost of achieving one more patient successfully treated with anidulafungin, caspofungin, and micafungin compared to fluconazole was €17,199, €23,962, and €27,339, respectively. The result remained stable, despite modification of the duration of the first-line and second-line treatments, as well as most of the dosing regimens. The probabilistic analysis also remained stable.ConclusionIn accordance with this economic study, anidulafungin would produce savings and would be the dominant treatment compared with micafungin and caspofungin in nonneutropenic adult patients with candidemia and/or invasive candidiasis in intensive care units in Spain.

show abstract

Recomendaciones sobre el tratamiento de la candidiasis invasiva y otras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011

Cited by 64 publications

References 148 publications

Manifestaciones orales en pacientes con diabetes mellitus tipo 2 atendidos en el Hospital Alberto Sabogal

Manifestaciones orales en pacientes con diabetes mellitus tipo 2 atendidos en el Hospital Alberto Sabogal

Infección nosocomial en el paciente receptor de un trasplante de órgano sólido o de precursores hematopoyéticos

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients

Contact Info

Product

Resources

About